Clik here to view.
As digital health unicorns are pressured to do more with less, Transcarent...
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Transcarent’s $126 million Series D round, which in May bumped its valuation to $2.2 billion, stands...
View ArticleClik here to view.
LabCentral helped create 6,300 jobs and 19 IPOs. Amid a slump, demand for lab...
When LabCentral celebrated its 10th anniversary last year, it was a bittersweet moment. The incubator has helped hundreds of biotechs launch and gain their footing. But startups, especially those with...
View ArticleLilly gets June adcomm for Alzheimer's drug donanemab, following earlier delay
Eli Lilly will face questions from a panel of Alzheimer’s experts on June 10, setting up an approval decision for donanemab after a surprise delay by the FDA in early March. The drug will go before the...
View ArticleLykos’ MDMA therapy to go before FDA committee; GSK expands work with BioVersys
Plus, news about Eledon and Travere Therapeutics: Lykos Therapeutics’ MDMA therapy gets an adcomm date: An FDA advisory committee is scheduled to meet June 4 to weigh the benefits and risks of the...
View ArticleFrom the editor: Our final edition of Endpoints MarketingRx
To our MarketingRx readers — Last week, we made the decision to shut down Endpoints MarketingRx. Over the last year, Endpoints News has put more resources into our core biopharma and healthcare...
View ArticleHow insurance upstart Alignment kept medical costs in check while Medicare...
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) High medical costs ate away at the profits of big Medicare Advantage insurers CVS Health and Humana in...
View ArticleAntitrust, AI and Alzheimer’s: Join us in New York next week
On May 16 in New York, Endpoints News and the Financial Times are teaming up to host the US Pharma and Biotech Summit. I’ve been deeply involved in planning our interviews and panels, and we have a...
View ArticleClik here to view.
Exclusive: Engineered B cell therapy startup Walking Fish shuts down
Walking Fish Therapeutics, a biotech startup that attempted to create engineered B cell therapies, has shuttered, founder Rusty Williams confirmed to Endpoints News. The South San Francisco biotech...
View ArticleHouse Oversight chair presses FDA on China amid growing tensions
House Oversight Committee Chair James Comer (R-KY) is pressing the FDA to share more information on its presence in China amid growing concerns on Capitol Hill about Chinese involvement in biotech and...
View ArticleClik here to view.
Madrigal 'encouraged' by early launch progress of landmark NASH drug
Madrigal Pharmaceuticals is “making great progress” on the rollout of its NASH drug Rezdiffra, executives said less than a month post-launch. Rezdiffra was approved in March as the first treatment for...
View ArticleWhite House unveils long-awaited policy on overseeing research of concern
The White House Office of Science and Technology Policy on Tuesday released its long-awaited policy plans for overseeing research that poses risks if misapplied. The initial reviews from experts are...
View ArticlePatient dies in Pfizer’s Phase 2 Duchenne muscular dystrophy trial
A Duchenne muscular dystrophy patient died of cardiac arrest on Friday in a Phase 2 trial of Pfizer’s gene therapy, the pharma company confirmed. The patient received fordadistrogene movaparvovec in...
View ArticleOscar is winding down its small employer health plans with Cigna
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Oscar Health said Tuesday it plans to stop selling health coverage to small businesses in partnership...
View ArticleAstraZeneca pulls Covid-19 vaccine globally as the pharma sees 'no future...
AstraZeneca is withdrawing its Oxford-collaborated Covid-19 vaccine from global markets, the UK-based pharma company confirmed in a statement to Endpoints News on Tuesday. The spokesperson said...
View ArticleTeva’s antipsychotic asset passes Phase 3 test in schizophrenia
Teva said Wednesday morning that its schizophrenia drug succeeded in a Phase 3 trial with signs of a differentiated safety profile versus standard of care. The Phase 3 SOLARIS trial set TEV-‘749 — a...
View ArticleClik here to view.
Employers are pulling back from providing mental health benefits, Talkspace...
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Talkspace CEO Jon Cohen told investors during an earnings call Tuesday that some employers have decided...
View ArticleClik here to view.
After CRISPR baby scandal shut down work for years, China gene editing...
A half-decade after a scientist’s reckless experiment with human embryos put a stop to much of China’s clinical work on CRISPR gene editing, local researchers are once again performing human studies of...
View ArticleClik here to view.
Isomorphic, Google DeepMind publish latest AI model AlphaFold 3
Google DeepMind and Isomorphic Labs unveiled the newest version of AlphaFold, taking its flagship AI model far beyond predicting the structure of a single protein. AlphaFold 3 can now predict a range...
View ArticleMarinus lays off 20% of workforce, cuts costs to stay afloat
Marinus Pharmaceuticals is cutting about 20% of its workforce and making other cost-cutting changes to extend its cash runway into the first quarter of 2025. The company said Wednesday that it had...
View ArticlePharming ends deal with Orchard; Seres considers cost-cutting
Plus, news about Think Bioscience and Apellis: Pharming axes Orchard pact: The Dutch biopharma terminated a research collaboration and licensing agreement with Orchard Therapeutics due to “current...
View Article